Sarepta CEO Sheds Some Sway Over Management

Sarepta Therapeutics Inc., which is seeking U.S. approval for a drug to treat a rare childhood disease, has recently moved to limit CEO Chris Garabedian's broad sway over operations, especially his role in talks with the FDA.



from WSJ.com: US Business http://ift.tt/WM33Pn

via IFTTT